Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

下载PDF

导出

摘要 Background:The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied.

作者 Deepak L Bhatt

机构地区不详

出处《四川生理科学杂志》 2020年第4期391-391,共1页 Sichuan Journal of Physiological Sciences

关键词 KIDNEY CARDIOVASCULAR DIABETES

分类号 R587.2 [医药卫生—内分泌] R692.9 [医药卫生—泌尿科学]

引文网络
相关文献

1Li Zhang,Shuai Xue,Jie Hou,Guang Chen,Zhong-Gao Xu.Endothelin receptor antagonists for the treatment of diabetic nephropathy:A meta-analysis and systematic review[J].World Journal of Diabetes,2020,11(11):553-566. 被引量：4
2Liliane Mfeukeu-Kuate,Jean-Claude Katte,Krystel Ebo,Jean Claude Mbanya,Eugene Sobngwi.Short Term Use of Empagliflozin Does Not Improve Left Ventricular Function in Non-Diabetic Hypertensive Patients: Results from a Non-Randomised Controlled Trial[J].World Journal of Cardiovascular Diseases,2020,10(8):563-571.
3Liu Yue,Qin Zhu-Yun,Yang Xin,Tang Rong,Gao Ling-Yun.WeChat Group of Chest Pain Center for Patients with Acute ST-segment Elevation Myocardial Infarction:Faster Treatment Speed and Better Prognosis[J].Cardiovascular Innovations and Applications,2020(4):97-102. 被引量：2
4Bo WANG,Hui-qing LIN,Fei LI,Zhang-fan MAO,Nian-guo DONG.Aβ40 Promotes the Osteoblastic Differentiation of Aortic Valve Interstitial Cells through the RAGE Pathway[J].Current Medical Science,2020,40(5):931-936. 被引量：1

四川生理科学杂志

2020年第4期

浏览历史

内容加载中请稍等...

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

相关作者

相关机构

相关主题

浏览历史